|
|
 |
|
Viewing report
|
|
|
|
Commercial and Pipeline Insight: Infertility - Optimizing a market bounded by social opinion and physician preference
Datamonitor, Oct 2007, Pages: 189
Introduction
The market for infertility drugs is a complex and dynamic arena shaped by numerous factors such as changing social attitudes, national legislation, and prescriber preferences. Brand strength and diverse portfolios have allowed Organon, Merck Serono and Ferring to secure a firm foothold in the market, worth over $1 billion in 2006, and represent tough competition.
Scope
Analysis of patient potential, unmet needs, market dynamics, and clinical trial design in infertility, supported by opinion leader comment Assessment of pipeline drugs and future treatment trends and their impact on prescribing patterns and behavior Patient based and sales based market forecasts to 2016, the latter providing a breakdown by region, drug class, marketed brands and pipeline drugs Coverage of emerging infertility markets which, in light of reproductive tourism, may offer revenue growth potential
Highlights
Key differentiators will permit Organons Org-36286 (corifollitropin alpha) and Merck Seronos Pergoveris (r-FSH and r-LH), to cannibalize some share from their proprietors franchise leading therapies. However, these agents do not appear to satisfy unmet need and this will prevent sales from rivaling Puregon and Menopur (hMG). The lack of education of non-specialist physicians limits the number of women receiving treatment. It should be a primary goal of the market to make these doctors more knowledgeable and to implement incentives to encourage patient referral. New opportunities exist in the development of products to support embryological techniques; cryopreservation, microarrays and in vitro maturation. These procedures will expand the treatable patient population as all women with the intention of preserving and protecting embryos will be eligible for treatment, not just those that are infertile.
Reasons to Purchase
Quantify the future size of the infertility market and the number of women eligible for infertility treatment to 2016 in the US, 5EU, and Japan Understand unmet needs and opportunities in the infertility market based on key opinion leader comments Benchmark key late-stage infertility compounds against current market leading brands
Customers who bought this item also bought
Stakeholder Insight: Infertility - Undifferentiated Drugs Force need to Strengthen Prescriber and Payer Relationship
Treatment Trends in Infertility
The Global Market For Hormonal Contraceptives and Infertility Drugs, 2005-2012
Women's Health Series: Is There Change Ahead for the Female Infertility Market?
Analysis of the European Infertility Treatment Markets
Stakeholder Opinion: Atopic Dermatitis - A High Level of Unmet Need Creates Market Opportunities
Infertility Therapy Area Pipeline Report
Emerging Markets in Infertility: Treatment Trends in Select Asian, Central and Eastern European, and Latin American Markets
Womens Health Infertility
Pipeline Insight: HIV - Novel NNRTIs address crucial unmet need
World Contraceptive and Infertility Drug Markets
Pipeline Insight: Acute Stroke: Commercial Risk Offsets High Unmet Need
|
|
|
|
